This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Pharmacy Europe     Newsletter    Login            

Press Releases

Take a look at a selection of our recent media coverage:

Scottish data suggest COVID-19 vaccines protect against Delta variant of concern

28th June 2021

Early findings from a Scottish study indicate that, in fully vaccinated individuals, COVID-19 vaccines are protective against the Delta variant.

With the emergence of COVID-19 variants, there is a race to ensure that the whole adult population is vaccinated to reduce the risk of severe illness and hospitalisation. But what is the real-world effectiveness against the predominant COVID-19 variants?

This was a question posed in a preliminary analysis of data from EAVE II, a Scotland-wide surveillance programme which contains data on 5.4 million people (around 99% of the Scottish population), by researchers from Public Health Scotland.

In a letter to the Lancet, the researchers used this database to profile COVID-19 patients and explore the risk of hospitalisation for the virus and to estimate the effectiveness of vaccines at preventing hospital admissions.

They focused on two COVID-19 variants of concern (VOC); the alpha VOC (S gene negative) and the Delta VOC (S gene positive). The analysis was based on all individuals who had a PCR test and compared the proportion of cases which were positive among individuals who had been vaccinated with those who were unvaccinated.

The team defined a COVID-19 hospital admission as being within 14 days of testing positive for virus or individuals who tested positive within 2 days of hospitalisation. The period of analysis was 1 April to 6 June 2021.


Prior to the period of analysis, 44.7% of the population in Scotland had received at least one dose of a COVID-19 vaccine and 7.6% had been fully vaccinated. By the end of the study period (6 June), the proportion of adults who had received at least one vaccine dose rose to 59.4% and 39.4% had been fully vaccinated.

There were 19,543 confirmed positive COVID-19 infections during the period of study, of whom 377 were admitted to hospital. In addition, 7723 (39.5%) of infections and 124 (35.5%) of hospital admissions were for the Delta VOC and 70% of infections occurred in those without any vaccination.

Using regression analysis, the researchers calculated that delta VOC cases were associated with an increased risk of hospitalisation (hazard ratio, HR = 1.85, 95% CI 1.39 – 2.47) compared with the Alpha VOC. Moreover, the risk of hospitalisation increased with the number of COVID-19 relevant co-morbidities.

Among those infected with the alpha VOC, the risk of hospitalisation was significantly reduced (HR = 0.28) for vaccinated compared to unvaccinated individuals. Similarly, the risk was reduced among those infected with the delta VOC (HR = 0.38).

In terms of vaccine effectiveness in the whole cohort, 14 days after being fully vaccinated with the BNT162b vaccine, there was a good level of protection against the alpha VOC although this was reduced for the delta VOC (92% vs 79%, Alpha VOC vs Delta VOC). In contrast, protection with the ChAdOx1 was lower (73% vs 60%, alpha VOC vs delta VOC).

In summarising their findings, the authors noted that the risk of hospitalisation was nearly double with the Delta VOC compared with the Alpha VOC. Moreover, while the results suggested that the BNT162b vaccine appeared to be more effective against the Delta VOC, the small number of cases meant that these results should be interpreted with caution.

Shiekh A et al. SARS-CoV-2 Delta VOC in Scotland: Demographics, Risk of Hospital Admission, and Vaccine Effectiveness. Lancet 2021.

More evidence for the protective effect of vitamin D in COVID-19

29th September 2020

Much has been written during the current pandemic inferring that vitamin D has a protective role against COVID-19.

Although in a recent review, NICE concluded that there was no evidence to support either a preventative or treatment role for vitamin D, new evidence from an analysis of a large patient cohort, suggests an inverse relationship between levels and positive COVID-19 status, implying that the vitamin has a protective role.

A team of US researchers retrospectively analysed a large, anonymous patient data set 50 US states and the District of Columbia between March and June 2020, for whom 25-hydroxyvitamin D (25(OH)D) levels were recorded in the previous 12 months. They limited their analysis to one COVID-19 test result per patient and included all available demographics including ethnicity and categorised 25(OH)D status as either low (<20ng/ml), adequate (30-34ng/ml) or higher ( >60ng/ml).

In total, 191,779 patients were included with a mean age was 54 years (68% female) and overall the COVID-19 positivity rate was 9.3%. When examining the relationship between 25(OH)D levels and COVID-19 positivity, the rate was highest among those with a low vitamin D status (12.5%) and decreased as it improved, being 8.1% for those with adequate levels and 5.9% among those with the highest levels.

In terms of ethnicity, COVID-19 positive rates were highest in black individuals (15.7%) compared to Hispanics (12.8%) and lowest in white, non-Hispanics (7.2%, p< 0.001 for both comparisons). Furthermore, the difference in positivity rates between ethnic groups was reflected in mean 25(OH)D levels, which were 33.0 vs 29.1 vs 28.8 ng/ml for white, blacks and Hispanic individuals (p< 0.001) respectively. In regression analysis, there was a strong association between vitamin D levels and lower COVID-19 after adjustment for all demographic factors (adjusted odds ratio = 0.98 per ng/ml increment).

The authors concluded that their findings provide a further rationale to explore the role of vitamin D supplementation to reduce the risk of COVID-19 infection.

Kaufman HW et al. SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels. PLoS ONE 15(9): e0239252. 10.1371/journal.pone.0239252